These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 3898140

  • 1. BCG in the management of superficial bladder cancer.
    Robinson MR.
    Prog Clin Biol Res; 1985; 185B():161-6. PubMed ID: 3898140
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Topical BCG for recurrent superficial bladder cancer.
    Lancet; 1991 Apr 06; 337(8745):821-2. PubMed ID: 1672916
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Management of superficial bladder carcinoma with BCG. Long term follow-up.
    Martínez-Piñeiro JA.
    Prog Clin Biol Res; 1984 Apr 06; 162B():335-45. PubMed ID: 6438642
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [The immunotherapy of bladder tumors and the immunoprophylaxis of disease recurrence].
    Korovin AI, Savvin VT.
    Urol Nefrol (Mosk); 1996 Apr 06; (1):19-21. PubMed ID: 8659034
    [Abstract] [Full Text] [Related]

  • 11. The optimal management of T1G3 bladder cancer.
    Emiliozzi P, Pansadoro A, Pansadoro V.
    BJU Int; 2008 Nov 06; 102(9 Pt B):1265-73. PubMed ID: 19035891
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
    Shekarsarai H, Zlotta AR, Drowart A, Van Vooren JP, De Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman CC, Huygen K.
    Acta Urol Belg; 1997 Mar 06; 65(1):1-4. PubMed ID: 9245197
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Adjuvant BCG immunotherapy in the management of superficial bladder tumors].
    Somogyi L, Szántó A, Polyák L, Baranyay F, Drinóczy M.
    Orv Hetil; 1993 Aug 22; 134(34):1851-6. PubMed ID: 8355975
    [Abstract] [Full Text] [Related]

  • 16. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E, Martínez-Piñeiro Lorenzo L, Martínez-Piñeiro Caramés JA, de la Peña Barthel JJ.
    Arch Esp Urol; 2000 Dec 22; 53(10):879-92. PubMed ID: 11213392
    [Abstract] [Full Text] [Related]

  • 17. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr 22; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
    Yamada Y, Washida H, Tozawa K, Honma H, Kang K.
    Hinyokika Kiyo; 1994 Jul 22; 40(7):575-9. PubMed ID: 8085517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.